Kalbe Farma Tbk PTKLBF:JKT

1,690
35.00 / 2.11%
42.17m
0.60%
0.7194
Close in IDRToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of Aug 28 2015 10:07 BST.

Consensus recommendation

As of Aug 21, 2015, the consensus forecast amongst 19 polled investment analysts covering Kalbe Farma Tbk PT advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts improved on Aug 17, 2015. The previous consensus forecast advised investors to hold their position in Kalbe Farma Tbk PT.

Previous recommendations
Last year3 months ago2 months ago4 weeks agoLatest
Mouseover chart recommendation details.
Latest recommendation
Buy5
Outperform4
Hold6
Underperform4
Sell0
No opinion0

Share price forecast

The 17 analysts offering 12 month price targets for Kalbe Farma Tbk PT have a median target of 1,820, with a high estimate of 2,200 and a low estimate of 1,300. The median estimate represents a 7.69% increase from the last price of 1,690. View Full Financials

High+30.2 %2,200
Med+7.7 %1,820
Low-23.1 %1,300

Dividends

In 2014, Kalbe Farma Tbk PT reported a dividend of 19.00 IDR, which represents a 11.76% increase over last year. The 14 analysts covering the company expect dividends of 21.62 IDR for the upcoming fiscal year, an increase of 13.81%. View Full Financials

Div growth (TTM)+11.76 %
  • Mouseover chart for details.
  • Dividend forecast
  • Quarter 1
  • Quarter 2
  • Quarter 3
  • Quarter 4

Earnings history & estimates

On Jul 31, 2015, Kalbe Farma Tbk PT reported 2nd quarter 2015 earnings of 12.00 per share. This result was in line with the expectation of the one analyst following the company and exceeded last year's 2nd quarter results by 20.00%.
The next earnings announcement is expected on Oct 29, 2015. View Full Interim Financials

Average growth rate+8.98 %

Kalbe Farma Tbk PT reported annual 2014 earnings of 44.00 per share on Mar 30, 2015. View Full Annual Financials

Average growth rate+12.64 %
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement

Revenue

PT. Kalbe Farma Tbk. had 2nd quarter 2015 revenues of 4.47bn. This missed the 4.69bn consensus estimate of the 2 analysts following the company. This was 3.71% above the prior year's 2nd quarter results. View Full Interim Financials

Average growth rate+1.06 %

PT. Kalbe Farma Tbk. had revenues for the full year 2014 of 17.37bn. This was 8.54% above the prior year's results. View Full Annual Financials

Average growth rate+14.39 %
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.